Communiqués Surmodics, Inc.

Actions

SRDX

US8688731004

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 14/06/2024			Varia. 5j.	Varia. 1 janv.
41,95 ^USD	-0,12 %		0,00 %	+15,41 %

10/06	Surmodics signe un accord d'achat groupé avec Premier	MT
10/06	Surmodics, Inc. reçoit un accord sur les produits de thrombectomie avec Premier, Inc.	CI

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Kuehn Law Encourages, FFNW, HCP, CALB, and SRDX Investors to Contact Law Firm	14:09	PR
Surmodics Awarded Thrombectomy Products Agreement with Premier, Inc.	10/06	BU
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Surmodics, Inc.	30/05	PR
Shareholder Alert: Ademi LLP investigates whether Surmodics, Inc. has obtained a Fair Price for its Public Shareholders	29/05	PR
SRDX Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Surmodics to GTCR	29/05	AQ
SRDX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Surmodics, Inc. Is Fair to Shareholders	29/05	BU
Surmodics Enters into Definitive Agreement to be Acquired by GTCR for $43.00 Per Share in Cash, Representing an Approximate Equity Value of $627 Million	29/05	BU
SurModics: Fiscal Q2 Earnings Snapshot	01/05	AQ
Surmodics Reports Second Quarter of Fiscal Year 2024 Financial Results; Updates Fiscal Year 2024 Financial Guidance	01/05	BU
Surmodics to Report Second Quarter of Fiscal 2024 Financial Results on May 1	22/04	AQ
Surmodics to Report Second Quarter of Fiscal 2024 Financial Results on May 1	19/04	BU
Surmodics to Participate in Upcoming Investor Conferences in March and April	27/02	BU
Surmodics Reports First Quarter of Fiscal Year 2024 Financial Results, Updates Fiscal Year 2024 Financial Guidance	02/02	AQ
SurModics: Fiscal Q1 Earnings Snapshot	01/02	AQ
Surmodics Reports First Quarter of Fiscal Year 2024 Financial Results; Updates Fiscal Year 2024 Financial Guidance	01/02	BU
Surmodics Announces Successful Early Clinical Use of Pounce LP Thrombectomy System, Designed to Address a Critical, Unmet Need by Facilitating Removal of Thrombi and Emboli below the Knee	23/01	AQ
Surmodics Announces Successful Early Clinical Use of Pounce™ LP (Low Profile) Thrombectomy System, Designed to Address a Critical, Unmet Need by Facilitating Removal of Thrombi and Emboli Below the Knee	22/01	BU
Surmodics to Report First Quarter of Fiscal 2024 Financial Results on February 1	16/01	BU
Surmodics to Host Virtual Annual Meeting of Shareholders	16/01	BU
Surmodics Announces TRANSCEND Trial 36-Month Data Presented at 50th Annual VEITH Symposium	16/11	BU

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Surmodics, Inc.

Actions

SRDX

US8688731004

Communiqués

Filtres